22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
07:00 , Aug 16, 2016 |  BC Extra  |  Financial News

Advaxis raises $30M in direct offering

Advaxis Inc. (NASDAQ:ADXS) raised $30 million through the sale of about 2.2 million shares at $13.50 in a registered direct offering with undisclosed institutional investors. The deal price is a 9% discount to Advaxis' close...
07:00 , Aug 15, 2016 |  BioCentury  |  Product Development

No antigen left behind

Amgen Inc. partnered with Advaxis Inc. to develop a personalized neoantigen therapy platform with potential to invoke a broad immune response by both stimulating the immune system on multiple fronts and delivering the full repertoire...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Advaxis, Amgen deal

Advaxis granted Amgen exclusive, worldwide rights to develop and commercialize ADXS-NEO . Advaxis will receive $40 million up front. Advaxis is eligible for up to $475 million in milestones, plus high single- to mid- double-digit...
07:00 , Aug 2, 2016 |  BC Extra  |  Company News

Amgen licenses Advaxis' neoantigen therapy

Advaxis Inc. (NASDAQ:ADXS) jumped $2.61 (31%) to $11.08 on Tuesday after it granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide rights to develop and commercialize ADXS-NEO, a patient-specific cancer immunotherapy that is expected to start clinical testing...